Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3HP.

Lelia H Chaisson,Fred C Semitala, Florence Nangobi, Samantha Steinmetz,Carina Marquez,Derek T Armstrong,Bishop Opira,Moses R Kamya,Patrick P J Phillips,David W Dowdy,Christina Yoon

AIDS (London, England)（2023）

引用 1|浏览26

暂无评分

摘要

Co-administration of TLD+3HP was well-tolerated. However, those who received TLD+3HP were less likely to achieve viral suppression within six-months compared to those who received TLD alone.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要